A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: procedure (650), etiquette (1), practice (609)

MyelomaMPTMelphalan(PO)PrednisoloneThalidomideVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPT-MELPHALAN (PO)-PREDNISOLONE-THALIDOMIDE Regimen Multiple Myeloma – MPT-Melphalan (PO)-Prednisolone-Thalidomide Indication First line treatment
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPTMelphalanPOPrednisoloneThalidomideVer1.pdf

Nivolumab 480mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its marketing
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description
Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within its marketing
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Lenvatinib(60kg or greater)

Description
Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is indicated where either; - the patient has a
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf

Lenvatinib(59kg or less)

Description
Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is indicated where either; - the patient has a
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf

Nivolumab_240mg

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The treatment
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

HSCTAlemtuzumabFludarabineMelphalan-Related_Methotrexate_GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GvHD) RELATED DONOR CONDITIONING This regimen will only be available to prescribe
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-Related-Methotrexate-GvHD.pdf

Cetuximab-Encorafenib

Description
Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-ENCORAFENIB Regimen • Colorectal Cancer – Cetuximab-Encorafenib Indication • Cetuximab and encorafenib can be used where; - the patient
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Encorafenib.pdf

HSCTCyclophosphamideTBI_Related_Methotrexate_GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION (TBI)-METHOTREXATE (GvHD) Related Donor Conditioning This regimen will only be available
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTCyclophosphamideTBI-Related-Methotrexate-GvHD.pdf

HSCTAlemtuzumabCyclophosphamideTBI_VUD_Methotrexate_GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION (TBI)METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) Conditioning This regimen will
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabCyclophosphamideTBI-VUD-Methotrexate-GvHD.pdf
311 to 320 of 698
Previous … 30 31 32 33 34 … Next